Next-level precision medicine: why the theragnostic approach is the future.
Q J Nucl Med Mol Imaging
; 68(2): 152-159, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38860276
ABSTRACT
Theragnostics represents one of the most innovative fields of precision medicine with a huge potential in the field of oncology in the next years. The use of a pair of selective radiopharmaceuticals for cellular receptors, used for diagnostic and therapeutic purposes (PRRT), finds applications in the Neuroendocrine tumors and metastatic Castration-Resistant prostate cancer (mCRPC) thanks, respectively, to somatostatin receptor agonists and PSMA-based peptides. Further evolutions of theragnostics will be possible to the radioimmunoconjugates used both in the diagnostic (Immuno-PET) and in the therapeutic fields (radioimmunotherapy). It is evident that in the "omics-era," theragnostics could become a necessary method, not only in order to improve our knowledge of tumor biology, but also, to find more and more targeted therapies in a multidisciplinary context and in a tailor-based approach.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Medicina de Precisión
Límite:
Humans
/
Male
Idioma:
En
Revista:
Q J Nucl Med Mol Imaging
Asunto de la revista:
MEDICINA NUCLEAR
Año:
2024
Tipo del documento:
Article
País de afiliación:
Italia
Pais de publicación:
Italia